8-K: Abbott Delivers Strong Q3, Reaffirms Full-Year Guidance

Abbott Laboratories reported robust third-quarter sales growth, driven by its Medical Devices and Established Pharmaceuticals segments, while reaffirming its full-year financial outlook.

Summary

• Third-quarter 2025 reported sales increased 6.9% to $11.369 billion, compared to $10.635 billion in the prior year.
• Organic sales growth for Q3 2025 was 5.5%, or 7.5% when excluding COVID-19 testing-related sales.
• GAAP diluted EPS for Q3 2025 was $0.94, remaining flat compared to Q3 2024.
• Adjusted diluted EPS for Q3 2025 increased 7.4% to $1.30, up from $1.21 in Q3 2024.
• Reported operating margin was 18.1% of sales, with an adjusted operating margin of 23.0%, reflecting a 40 basis point increase.
• Year-to-date (nine months ended September 30, 2025) reported sales grew 6.1% to $32.869 billion.
• Year-to-date organic sales growth was 6.4%, or 7.7% excluding COVID-19 testing-related sales.
• Received regulatory approval in Japan for TriClip, a minimally invasive treatment for tricuspid regurgitation, in July 2025.
• Received CE Mark for an expanded indication for the Navitor transcatheter aortic valve implantation (TAVI) system in August 2025.
• New treatment guidelines issued at the European Society of Cardiology (ESC) Congress in August 2025 provided additional support for MitraClip and TriClip.
• Reaffirmed full-year 2025 organic sales growth guidance of 7.5% to 8.0% (excluding COVID-19 testing) or 6.0% to 7.0% (including COVID-19 testing).
• Reaffirmed the midpoint of full-year 2025 adjusted diluted EPS guidance and narrowed the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.
• Declared a quarterly dividend of $0.59 per share on September 19, 2025, marking the 407th consecutive quarterly dividend and 53 consecutive years of dividend increases.

Sentiment

Score: 7

Explanation: Abbott delivered solid third-quarter results with strong organic sales growth excluding COVID-19 testing and double-digit adjusted EPS growth. The Medical Devices and Established Pharmaceuticals segments performed exceptionally well, driven by innovative products and key emerging markets. While Diagnostics faced headwinds from declining COVID-19 testing and challenging conditions in China, the company reaffirmed its full-year guidance, indicating confidence in its ongoing performance and product pipeline. The flat GAAP EPS in Q3 and significant increase in taxes on earnings are notable but largely explained by specified items and tax adjustments.

Positives

• Strong overall organic sales growth of 7.5% in Q3 2025 when excluding COVID-19 testing-related sales.
• Adjusted diluted EPS increased 7.4% to $1.30 in Q3 2025 and 9.6% to $3.65 year-to-date.
• Adjusted operating margin increased by 40 basis points to 23.0% in Q3 2025.
• Medical Devices segment showed robust growth, with reported sales up 14.8% and organic sales up 12.5% in Q3 2025.
• Diabetes Care sales, within Medical Devices, reached $2.0 billion in Q3 2025, growing 20.5% on a reported basis and 17.2% organically.
• Double-digit growth was observed in Electrophysiology, Rhythm Management, Heart Failure, and Structural Heart within Medical Devices.
• Established Pharmaceuticals sales increased 7.5% reported and 7.1% organically in Q3 2025, driven by 11.1% organic growth in Key Emerging Markets.
• Adult Nutrition sales grew 5.8% reported and 5.4% organically, led by strong performance of Ensure and Glucerna brands.
• Received regulatory approval for TriClip in Japan and CE Mark for an expanded indication for the Navitor TAVI system, enhancing product portfolio.
• New ESC Congress guidelines provide additional clinical support for MitraClip and TriClip.
• Reaffirmed full-year 2025 guidance for organic sales growth and narrowed the adjusted diluted EPS range, indicating confidence in future performance.
• Maintained a strong commitment to shareholders with the 407th consecutive quarterly dividend and 53 consecutive years of dividend increases.

Negatives

• Diagnostics sales decreased 6.6% on a reported basis and 7.8% on an organic basis in Q3 2025.
• COVID-19 testing-related sales significantly declined to $69 million in Q3 2025 from $265 million in Q3 2024.
• Diagnostics growth was impacted by challenging market conditions in China, including volume-based procurement programs.
• GAAP diluted EPS remained flat at $0.94 in Q3 2025 compared to the prior year.
• Taxes on earnings increased significantly by 82.0% in Q3 2025 and 67.7% year-to-date, partly due to adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Risks

• Challenging market conditions in China, including the impact of volume-based procurement programs, could continue to affect Diagnostics sales.
• The significant decline in COVID-19 testing-related sales represents a continuing headwind for the Diagnostics segment.
• Economic, competitive, governmental, technological, and other factors, as detailed in the Annual Report on Form 10-K for the year ended December 31, 2024, may cause actual results to differ materially from forward-looking statements.
• Inability to predict with reasonable certainty the timing and impact of certain items such as restructuring, intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact GAAP results.

Future Outlook

Abbott reaffirms its full-year 2025 organic sales growth guidance of 7.5% to 8.0% (excluding COVID-19 testing-related sales) or 6.0% to 7.0% (including COVID-19 testing-related sales). The midpoint of the full-year 2025 adjusted diluted EPS guidance range is also reaffirmed, with the range narrowed to $5.12 to $5.18, reflecting double-digit growth at the midpoint. The company is unable to provide related GAAP financial measures on a forward-looking basis due to the unpredictable timing and impact of certain items like restructuring, intangible asset impairments, acquisition-related expenses, and foreign exchange.

Management Comments

• Robert B. Ford, chairman and chief executive officer, stated: "Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance. Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders."

Industry Context

The decline in COVID-19 testing sales reflects a broader industry trend as the global health landscape transitions from a pandemic to an endemic phase, impacting diagnostics companies. Abbott's strong growth in Medical Devices, particularly in Diabetes Care with continuous glucose monitors, aligns with increasing global demand for advanced and minimally invasive solutions for chronic disease management. The regulatory approvals for TriClip and Navitor TAVI system, coupled with supportive new treatment guidelines, underscore continued innovation and market expansion in the competitive cardiovascular and structural heart device segments. Challenges in China's diagnostics market, including volume-based procurement programs, are a known headwind for many multinational healthcare companies operating in that region.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry competitors or global benchmarks.
• However, the double-digit organic growth in Diabetes Care (17.2%) and other Medical Device segments is generally considered strong within the healthcare industry, indicating robust market penetration and product acceptance.
• The decline in COVID-19 testing sales in Diagnostics reflects a broader industry trend as the pandemic transitions to an endemic phase, impacting most companies that had significant revenue streams from these products.

Stakeholder Impact

• Shareholders: Positive impact from strong sales and adjusted EPS growth, reaffirmed guidance, and continued dividend increases. Potential concern from flat GAAP EPS and increased tax expenses.
• Customers: Benefit from new product approvals (TriClip, Navitor) and continued innovation in medical devices and nutrition.
• Employees: Continued strong performance suggests stability and ongoing business operations.
• Creditors: Strong financial health and consistent performance generally provide reassurance.

Next Steps

• Abbott will live-webcast its third-quarter earnings conference call on October 15, 2025, at 8 a.m. Central time.
• The declared quarterly dividend of $0.59 per share is payable on November 17, 2025.

Key Dates

Recommendation

Abbott's third-quarter results demonstrate consistent, high-quality performance driven by a strong product pipeline, particularly in Medical Devices and Established Pharmaceuticals. The reaffirmation and narrowing of full-year adjusted EPS guidance, alongside a long history of dividend increases, signals stability and management confidence. However, the flat GAAP EPS for the quarter and ongoing challenges in the Diagnostics segment due to declining COVID-19 testing and market conditions in China present some headwinds. While the company is well-positioned for long-term value, these factors suggest a 'hold' recommendation for investors seeking continued growth with an awareness of existing challenges, rather than a 'buy' for immediate significant upside based solely on this report.

Keywords

Abbott Laboratories, ABT, Q3 2025 Earnings, Financial Results, Medical Devices, Diagnostics, Nutrition, Established Pharmaceuticals, Sales Growth, EPS, Dividend, TriClip, Navitor, Continuous Glucose Monitors, FreeStyle Libre, Healthcare